Saumbon, Arabella .
HRN: 27-13-78 Sex: FemalePatient Encounter
Audit Details
Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
05/20/2025
AMIKACIN 250MG/ML, 2ML (VIAL/AMP)
05/20/2025
05/27/2025
IV
138mg
OD
Sepsis
Waiting Final Action
Indication: Empiric Type of Infection: Bloodstream Compliance to guidelines: Compliant To Guidelines
Initial appropriateness: Yes
Final appropriateness: Yes
Overall appropriateness: Yes